Ask AI
ProCE Banner Activity

Optimizing the Use of Antibody–Drug Conjugates in Relapsed/Refractory DLBCL: Patient Selection, Clinical Challenges, and Future Directions

Clinical Thought

Expert commentary on the evolving role of antibody–drug conjugate use in patients with relapsed/refractory DLBCL, including answers to frequently asked questions from a live webinar audience of healthcare professionals with a focus on patient selection, clinical integration, management challenges, and future directions within an increasingly complex treatment landscape.

Released: May 14, 2026

Share

Provided by

ProCE Banner

Supporters

Supported by educational grants from ADC Therapeutics and Pfizer Inc.

ADC Therapeutics

Pfizer, Inc.

Target Audience

This program is intended for community teams caring for patients with DLBCL, including hematologists/oncologists, nurse practitioners, physician associates, pharmacists, nurses, and other healthcare professionals. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify the potential of novel antibody-drug conjugates to address unmet needs for patients with R/R DLBCL

  • Develop individualized treatment protocols for patients with R/R DLBCL based on the latest clinical data, guidelines, and patient-specific factors

  • Formulate multidisciplinary strategies to identify, prevent, and manage toxicities associated with antibody-drug conjugates for R/R DLBCL

  • Incorporate patient goals and preferences into shared decision-making to optimize R/R DLBCL treatment planning across the continuum of care

Disclosure

Primary Author

Brad Kahl, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeOne, Genentech, Incyte, Lilly, Merck, Pfizer, Roche.

Disclaimer

Generative AI tools may have been used to assist in the development and/or editorial refinement of content for this activity (eg, preliminary drafting, editing, and/or formatting). All AI-assisted content was reviewed, substantively edited, and validated by qualified faculty, planners, and reviewers to ensure accuracy, balance, and compliance with ACCME Standards for Integrity and Independence in Accredited Continuing Education.